On this page

SSD Cream

Silver Sulfadiazine · Cream

Prescription NDA TE AB RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
SSD Cream
Generic name
Silver Sulfadiazine
Dosage form
Cream
Route
Topical
Marketing category
NDA · NDA
Labeler
NuCare Pharmaceuticals, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
4
Packages
9
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Silver Sulfadiazine 10 g/1000g 106351 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
13

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Sulfonamide Antibacterial [EPC] EPC 6 members — no class page
Sulfonamides [CS] CS All 18 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
018578
Application type
NDA · New Drug Application
Approval date
February 25, 1982
Sponsor
DR REDDYS
Products on application
2
Submissions recorded
14
Products approved under application 018578.
Product Trade name Form Strength Ingredient Status TE Flags
018578-001 SSD CREAM SILVER SULFADIAZINE Prescription AB RLD RS
018578-003 SSD AF CREAM SILVER SULFADIAZINE Discontinued —

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 018578.
Type No. Action Status Date Review
Supplement 16 Manufacturing (CMC) Approved April 21, 2014 Standard
Supplement 13 Manufacturing (CMC) Approved May 24, 2000 Standard
Supplement 12 Manufacturing (CMC) Approved January 12, 1999 Standard
Supplement 11 Manufacturing (CMC) Approved January 11, 1995 Standard
Supplement 9 Manufacturing (CMC) Approved August 3, 1990 Standard
Supplement 8 Manufacturing (CMC) Approved July 11, 1990 Standard
Supplement 6 Labeling Approved July 11, 1990 —
Supplement 7 Manufacturing (CMC) Approved March 15, 1989 Standard
Supplement 5 Labeling Approved December 10, 1985 —
Supplement 1 Manufacturing (CMC) Approved January 29, 1985 Standard
Supplement 4 Manufacturing (CMC) Approved March 16, 1984 Standard
Supplement 3 Labeling Approved August 19, 1983 —
Supplement 2 Manufacturing (CMC) Approved May 12, 1983 Standard
Original application 1 Type 5 - New Formulation or New Manufacturer Approved February 25, 1982 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250612). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250612 HUMAN PRESCRIPTION DRUG · 20190424

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: FOR TOPICAL USE ONLY - NOT FOR OPHTHALMIC USE: Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided; Silver Sulfadiazine Cream is then applied under sterile conditions. The burn areas should be covered with Silver Sulfadiazine Cream at all times. The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed due to patient activity. Administration may be accomplished in minimal time because dressings are not required. However, if individual patient requirements make dressings necessary, they may be used. Reapply immediately after hydrotherapy. Treatment with Silver Sulfadiazine Cream should be continued until satisfactory healing has occurred or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Silver Sulfadiazine Cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. Because sulfonamide therapy is known to increase the possibility of kernicterus, Silver Sulfadiazine Cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

WARNING There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low. The use of Silver Sulfadiazine Cream in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Several cases of transient leucopenia have been reported in patients receiving silver sulfadiazine therapy. Leucopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy. Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. The incidence of leucopenia in various reports averages about 20%. A higher incidence has been seen in patients treated concurrently with cimetidine. Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis. Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture. Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias, agranulocytosis, aplastic anemia, thrombocytopenia, leucopenia, hemolytic anemia, dermatologic reactions, allergic reactions, Stevens-Johnson syndrome, exfoliative dermatitis, gastrointestinal reactions, hepatitis, hepatocellular necrosis, CNS reactions, and toxic nephrosis.

Description

openFDA Drug Labeling

DESCRPITION SSDTM (1% Silver Sulfadiazine Cream) and SSD AFTM (1% Silver Sulfadiazine Cream), 1% are topical antibacterial preparations which have as their active antimicrobial ingredient silver sulfadiazine. The active moiety is contained within an opaque, white, water miscible cream base. Each 1000 grams of SSD/SSD AF Cream contains 10 grams of silver sulfadiazine. Inactive Ingrediants: cetyl alcohol (SSD Cream only), isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methyl paraben, as a preservative. Silver sulfadiazine has an emprical formula of C 10 H 9 AgN 4 O 2 S, molecular weight of 357.14 and structural formula as shown: Structure for silver sulfadiazine

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED SSDTM (1% Silver Sulfadiazine) Cream : white to off-white cream. 50 gram jar NDC 43598-210-55 400 gram jar NDC 43598-210-40 25 gram tube NDC 43598-210-25 50 gram tube NDC 43598-210-50 85 gram tube NDC 43598-210-85 SSD AFTM (1% Silver Sulfadiazine) Cream : white to off-white cream. 50 gram jar NDC 43598-211-55 400 gram jar NDC 43598-211-40 Store at controlled room temperature 15° - 30°C (59° - 86°F) SSD is a trademark of Dr. Reddy's Laboratories, Inc. Manufactured by: Dr. Reddy's Laboratories Louisiana LLC Shreveport, LA 71106 USA Revised, June 2013

Adverse event reports

Source: openFDA FAERS
2,276
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: SILVER SULFADIAZINE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
43598-210-25 43598-210 Dr Reddys Laboratories Inc 25 g in 1 TUBE (43598-210-25) May 4, 2011
43598-210-40 43598-210 Dr Reddys Laboratories Inc 400 g in 1 JAR (43598-210-40) May 4, 2011
43598-210-50 43598-210 Dr Reddys Laboratories Inc 50 g in 1 TUBE (43598-210-50) May 4, 2011
43598-210-55 43598-210 Dr Reddys Laboratories Inc 50 g in 1 JAR (43598-210-55) May 4, 2011
43598-210-85 43598-210 Dr Reddys Laboratories Inc 85 g in 1 TUBE (43598-210-85) May 4, 2011
68071-3867-5 68071-3867 NuCare Pharmaceuticals, Inc. 50 g in 1 TUBE (68071-3867-5) June 13, 2025
68788-8074-2 68788-8074 Preferred Pharmaceuticals Inc. 25 g in 1 TUBE (68788-8074-2) August 27, 2021
68788-8074-5 68788-8074 Preferred Pharmaceuticals Inc. 50 g in 1 TUBE (68788-8074-5) August 27, 2021
60760-962-50 60760-962 St. Mary's Medical Park Pharmacy 50 g in 1 TUBE (60760-962-50) October 4, 2024
43598-210 43598-210 Dr Reddys Laboratories Inc — May 4, 2011
68071-3867 68071-3867 NuCare Pharmaceuticals, Inc. — May 4, 2011
68788-8074 68788-8074 Preferred Pharmaceuticals Inc. — August 27, 2021
60760-962 60760-962 St. Mary's Medical Park Pharmacy — October 4, 2024

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.